Compare Incyte Corporation (INCY) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United States Oil ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while United States Oil ETF trades at $127.22. The key difference: Incyte Corporation is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| INCY | USO | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $152.96 |
52-Week Low | $81.61 | $66.17 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
USO trades at $127.36, up 1.14% with bullish technical signals from moving averages. The stock faces mixed sentiment as oil markets balance supply disruptions from Middle East tensions against OPEC's downward demand revisions. Technical indicators show strong momentum with ADX signaling trend strength while RSI remains neutral, suggesting room for further movement.
The outlook remains volatile with geopolitical risks driving price action. Upside potential exists if Middle East supply constraints persist, but demand destruction concerns and inventory builds present headwinds. Investors should monitor Strait of Hormuz developments and EIA inventory data for directional catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
